Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

DexCom, Inc. (DXCM)

113.63   -0.87 (-0.76%) 03-24 12:06
Open: 114.26 Pre. Close: 114.5
High: 115.21 Low: 112.79
Volume: 441,877 Market Cap: 43,908(M)

Technical analysis

as of: 2023-03-24 10:43:07 AM
Overall:       
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 143.82     One year: 167.99
Support: Support1: 111.43    Support2: 104.19
Resistance: Resistance1: 123.13    Resistance2: 143.82
Pivot: 113.72
Moving Average: MA(5): 116.02     MA(20): 114.11
MA(100): 113.12     MA(250): 99.71
MACD: MACD(12,26): 0.7     Signal(9): 0.7
Stochastic oscillator: %K(14,3): 54.7     %D(3): 59.3
RSI: RSI(14): 51.2
52-week: High: 289.72  Low: 66.89
Average Vol(K): 3-Month: 2,478 (K)  10-Days: 1,793 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ DXCM ] has closed below upper band by 42.6%. Bollinger Bands are 33.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 116.92 - 117.71 117.71 - 118.36
Low: 111.82 - 112.58 112.58 - 113.21
Close: 113.38 - 114.62 114.62 - 115.65

Company Description

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Headline News

Fri, 24 Mar 2023
Dexcom (DXCM) Launches G6 Glucose Monitoring System in Canada - Zacks Investment Research

Thu, 23 Mar 2023
Price Over Earnings Overview: DexCom - DexCom (NASDAQ:DXCM) - Benzinga

Tue, 21 Mar 2023
Harbour Capital Advisors LLC Acquires 3257 Shares of DexCom ... - MarketBeat

Mon, 20 Mar 2023
DexCom Inc. stock rises Monday, outperforms market - MarketWatch

Mon, 20 Mar 2023
Is DexCom (DXCM) Stock Undervalued? - Yahoo Finance

Sun, 19 Mar 2023
Validea's Top Ten Healthcare Stocks Based On John Neff - 3/19/2023 - Nasdaq

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Outperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Medical Devices
Shares Out. 386 (M)
Shares Float 383 (M)
% Held by Insiders 0.4 (%)
% Held by Institutions 100.7 (%)
Shares Short 12,930 (K)
Shares Short P.Month 11,110 (K)

Stock Financials

EPS 0.81
EPS Est Next Qtl 0
EPS Est This Year -0.81
EPS Est Next Year -0.44
Book Value (p.s.) 5.51
Profit Margin (%) 11.7
Operating Margin (%) 13.4
Return on Assets (ttm) 4.7
Return on Equity (ttm) 16.3
Qtrly Rev. Growth 16.7
Gross Profit (p.s.) 4.86
Sales Per Share 7.53
EBITDA (p.s.) 1.37
Qtrly Earnings Growth 0
Operating Cash Flow 670 (M)
Levered Free Cash Flow 233 (M)

Stock Valuations

PE Ratio 139.58
PEG Ratio 3.6
Price to Book value 20.73
Price to Sales 15.19
Price to Cash Flow 66.06

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.